Dr. Nancy Holekamp joins the program to discuss her career development, the paradigm shift in terms of management of persistent subretinal fluid in wet AMD, strategies for improving AMD treatment including the port-delivery system and gene therapy. She also discusses her role in founding Women in Retina (WinR).
Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Dorc, Oxurion and Regeneron. Dr. Holekamp has received consulting fees from Allergan, Acucela, Apellis, Lineage Cell Therapeutics, Clearside Biosciences, Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, Notal Vision, Novartis, Polyactiva, and Regeneron. She is on the Speaker's Bureau for Allergan, Genentech, Novartis, Regeneron and Spark. She performs contracted research with Genentech, Gemini and Gyroscope and holds an intellectual property patent with Katalyst Surgical.
CME Information
Release: October 15, 2020; expires October 15, 2023
Reviewers: Purnima Patel, MD; Shriji Patel, MD; Carl Danzig, MD
Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.